κWhen microglia wind up with a belly full of lipid droplets, it’s a sign that the cells are rallying, perhaps in vain, to a neurodegenerative threat. But according to a study published July 10 in Cell ...

Machine learning software sharpens the diagnostic utility of FDG PET scans. StateViewer told apart nine neurodegenerative diseases with 93 percent accuracy. Using the program made radiologists three ...

Is Alzheimer’s disease different in people with Down’s? Two recent proteomics studies say yes. In the July 1 Nature Communications, scientists led by Erik Johnson at Emory University School of ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

Lina Schmidt, Dr.Contact Information Lina Schmidt, Dr.

Research News Parkinsonian disorders are difficult to diagnose. Clinical symptoms often overlap ...

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) (RFA-FD-25-017) Grants Home ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...